Literature DB >> 12965175

Immunogenetics of the response to HBsAg vaccination.

David R Milich1, Geert G Leroux-Roels.   

Abstract

The major envelope protein of the hepatitis B virus (HBV), the HBsAg, constitutes the current preventative vaccine, which represents the first subunit viral vaccine developed. The genetics of the immune response to HBsAg has been extensively studied both in humans and mice. Murine studies begun over 20 years ago indicated that at least two MHC class II and one MHC class III genes regulate anti-HBs immune responses. Additional MHC-linked genes influence the immune responses to the higher molecular weight (pre-S) components of the HBV envelope. The murine studies predicted even more complex MHC gene regulation of human immune responses to the HBsAg and that complexity certainly has been demonstrated during the ensuing years. This brief review is an attempt to summarize our current understanding of the MHC genes that influence the immune response to the HBsAg and possible mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965175     DOI: 10.1016/s1568-9972(03)00031-4

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  26 in total

1.  Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.

Authors:  Masatoshi Ishigami; Hideya Kamei; Taro Nakamura; Yoshiaki Katano; Hisami Ando; Tetsuya Kiuchi; Hidemi Goto
Journal:  J Gastroenterol       Date:  2010-09-11       Impact factor: 7.527

2.  Genetic determinants of immune-response to a polysaccharide vaccine for typhoid.

Authors:  Partha P Majumder; Herman F Staats; Neeta Sarkar-Roy; Binuja Varma; Trina Ghosh; Sujit Maiti; K Narayanasamy; Carol C Whisnant; James L Stephenson; Diane K Wagener
Journal:  Hugo J       Date:  2010-03-11

3.  Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

Authors:  I Desombere; T Cao; Y Gijbels; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins.

Authors:  Wei-Guo Hu; Jun Wei; Heng-Chuan Xia; Xin-Xiu Yang; Feng Li; Guang-Di Li; Yuan Wang; Zu-Chuan Zhang
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 5.  Old and new adjuvants for hepatitis B vaccines.

Authors:  Geert Leroux-Roels
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

Review 6.  Searching for the human genetic factors standing in the way of universally effective vaccines.

Authors:  Alexander J Mentzer; Daniel O'Connor; Andrew J Pollard; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

7.  Genomic correlates of variability in immune response to an oral cholera vaccine.

Authors:  Partha P Majumder; Neeta Sarkar-Roy; Herman Staats; T Ramamurthy; Sujit Maiti; Goutam Chowdhury; Carol C Whisnant; K Narayanasamy; Diane K Wagener
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

Review 8.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Authors:  Isabelle Desombere; Annick Willems; Yvonne Gijbels; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.

Authors:  Marjoleine L Op den Brouw; Rekha S Binda; Mark H van Roosmalen; Ulrike Protzer; Harry L A Janssen; Renate G van der Molen; Andrea M Woltman
Journal:  Immunology       Date:  2008-06-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.